ARTICLE | Product Development
Why tissue-agnostic drug development needs NGS to go mainstream
For tissue-agnostic drug development to go big, NGS needs to become routine with community oncologists
June 28, 2019 11:59 PM UTC
Next-generation sequencing is emerging as the rate-limiting factor for how fast and broadly tissue-agnostic drug development will take off in drug development. By engaging community oncologists, some companies hope to spread the word and enable more patients access to trials earlier in their disease.
This month saw the third agent approved based on its molecular target rather than the cancer’s tissue of origin, when Japan’s Ministry of Health, Labor & Welfare granted approval to Roche’s Rozlytrek entrecitinib to treat NTRK-positive cancer. ...